Evidence map›Paper›PMID 33374273›Full record

ArticleVaccines2020

N-terminal VP1 Truncations Favor

Ronja Pogan, Victor U Weiss, Kevin Bond, Jasmin Dülfer, Christoph Krisp, Nicholas Lyktey, Jürgen Müller-Guhl, Samuele Zoratto, Günter Allmaier, Martin F Jarrold and 3 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.3field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Norovirus-glycan interactions - how strong are they really?Biochemical Society transactions · 2022
    Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Ronja PoganHeinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Germany.
Victor U WeissInstitute of Chemical Technologies and Analytics, TU Wien, 1060 Vienna, Austria.ORCID 0000-0002-0056-6819
Kevin BondDepartment of Chemistry, Indiana University, Bloomington, IN 47405, USA.
Jasmin DülferHeinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Germany.ORCID 0000-0001-9614-7645
Christoph KrispMass Spectrometric Proteomics Group, Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Nicholas LykteyDepartment of Chemistry, Indiana University, Bloomington, IN 47405, USA.
Jürgen Müller-GuhlHeinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Germany.
Samuele ZorattoInstitute of Chemical Technologies and Analytics, TU Wien, 1060 Vienna, Austria.ORCID 0000-0002-1491-3404
Günter AllmaierInstitute of Chemical Technologies and Analytics, TU Wien, 1060 Vienna, Austria.
Martin F JarroldDepartment of Chemistry, Indiana University, Bloomington, IN 47405, USA.
Cesar Muñoz-FontelaPartner Site Hamburg-Lübeck-Borstel-Riems, Bernhard Nocht Institute for Tropical Medicine and German Center for Infection Research (DZIF), 20359 Hamburg, Germany.ORCID 0000-0002-7725-2586
Hartmut SchlüterMass Spectrometric Proteomics Group, Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.ORCID 0000-0002-9358-7036
Charlotte UetrechtHeinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Germany.ORCID 0000-0002-1991-7922
Leibniz Institute of Virology (LIV) · DEIndiana University Bloomington · USTU Wien · ATUniversität Hamburg · DEGerman Center for Infection Research · DE

Funding

Austrian Theodor Körner Fonds Austrian Theodor Körner FondsDFG FOR2327 VirocarbEU Cost BM1403EU Horizon 2020 731868Leibniz Association SAW-2014-HPI-4
6 · The paper itself

Abstract

Noroviruses cause immense sporadic gastroenteritis outbreaks worldwide. Emerging genotypes, which are divided based on the sequence of the major capsid protein VP1, further enhance this public threat. Self-assembling properties of the human norovirus major capsid protein VP1 are crucial for using virus-like particles (VLPs) for vaccine development. However, there is no vaccine available yet. Here, VLPs from different variants produced in insect cells were characterized in detail using a set of biophysical and structural tools. We used native mass spectrometry, gas-phase electrophoretic mobility molecular analysis, and proteomics to get clear insights into particle size, structure, and composition, as well as stability. Generally, noroviruses have been known to form mainly

Indexed as

capsid assemblyCDMSdifferential mobility analysisnative mass spectrometrynES GEMMAnorovirus

Identifiers

PMID33374273
PMCPMC7824077
OpenAlexW3113995279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.